More globally, analysis of GPX4 protein expression levels performed in up to forty different cancers show that besides AML, GPX4 is also elevated in most hematological malignancies including Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) [39]. Here, GPX4 is linked to non-Hodgkin lymphoma.